rituximab off-label
Selected indexed studies
- Off-Label Uses of Rituximab in Dermatology. (Curr Dermatol Rep, 2022) [PMID:36217351]
- Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. (Lancet Oncol, 2024) [PMID:38309282]
- Rituximab treatment in myasthenia gravis. (Front Neurol, 2023) [PMID:37849836]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. (2023) pubmed
- Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. (2021) pubmed
- Off-Label Uses of Rituximab in Dermatology. (2022) pubmed
- Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. (2024) pubmed
- Rituximab treatment in myasthenia gravis. (2023) pubmed
- Off-label uses of rituximab in dermatology. (2007) pubmed
- Off-label use of rituximab in systemic lupus erythematosus: a systematic review. (2010) pubmed
- Opportunities and limitations of B cell depletion approaches in SLE. (2025) pubmed
- Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. (2008) pubmed
- ALSUntangled #67: rituximab. (2023) pubmed